Helen Mann

11.6k citations

95 papers · 6.3k · 4 hit papers · h-index 32

Impact in

Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy

Papers in

Oncology 52
- Cancer Immunotherapy and Biomarkers 16
- Lung Cancer Research Studies 12
- Colorectal Cancer Treatments and Studies 11
- PARP inhibition in cancer therapy 11
- Pancreatic and Hepatic Oncology Research 9
Pulmonary and Respiratory Medicine 44
- Lung Cancer Treatments and Mutations 36
- Gastric Cancer Management and Outcomes 8
- Advanced Breast Cancer Therapies 5

Co-authors: Suresh S. Ramalingam (8 shared papers)Serban Ghiorghiu (8 shared papers)Yi‐Long Wu (9 shared papers)Frances A. Shepherd (5 shared papers)Myung‐Ju Ahn (6 shared papers)Tony Mok (13 shared papers)Chee Khoon Lee (4 shared papers)Willemijn S.M.E. Theelen (4 shared papers)
Journals: Annals of Oncology (17 papers)Journal of Clinical Oncology (14 papers)Journal of Thoracic Oncology (9 papers)Clinical Lung Cancer (5 papers)Cancer Research (4 papers)
Partner nations: United Kingdom United States Japan

In The Last Decade

Helen Mann

90 papers receiving 6.2k citations

Helen Mann's Hit Papers

align trajectories log scale

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer 2020 · 311 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Annals of Oncology
2017 Journal of Clinical Oncology
2016 New England Journal of Medicine
2016 The Lancet Oncology

Peers

Countries citing papers authored by Helen Mann

Since Specialization

Citations

This map shows the geographic impact of Helen Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Mann more than expected).

Fields of papers citing papers by Helen Mann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Mann. The network helps show where Helen Mann may publish in the future.

Co-authors

The 25 scholars most cited alongside Helen Mann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Helen Mann Line = papers co-authored together Helen Mann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 95 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer New England Journal of Medicine ·Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou Hit paper breakdown →	2016	2417
2	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study The Lancet Oncology ·Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi Hit paper breakdown →	2016	507
3	Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov, Serban Ghiorghiu, Daniel Stetson, Aleksandra Markovets, J. Carl Barrett, Kenneth S. Thress, Pasi A. Jänne Hit paper breakdown →	2017	382
4	TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer Annals of Oncology ·Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn Hit paper breakdown →	2020	311
5	Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer QUT ePrints (Queensland University of Technology) ·Tony Mok, Yi‐Long Wu, M. Ahn, M.C. Garassino, H. R. Kim, Sendhilnathan Ramalingam, F. Shepherd, Ya-Min He, H. Akamatsu, Willemijn S.M.E. Theelen, C.K. Lee, Michael Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou, Kenneth J. O’Byrne	2017	292
6	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy Gynecologic Oncology ·Susan M. Domchek, Carol Aghajanian, Ronnie Shapira‐Frommer, Rita K. Schmutzler, M. William Audeh, Michael Friedländer, Judith Balmañà, Gillian Mitchell, Georgeta Fried, Salomon M. Stemmer, Ayala Hubert, Ora Rosengarten, Niklas Loman, Jane Robertson, Helen Mann, Bella Kaufman	2015	220
7	Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis Annals of Oncology ·Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu	2020	191
8	Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety Annals of Oncology ·Ursula A. Matulonis, Richard T. Penson, S. M. Domchek, Bella Kaufman, Ronnie Shapira‐Frommer, M. William Audeh, S.B. Kaye, L. Rhoda Molife, Karen A. Gelmon, Jane Robertson, Helen Mann, Tony W. Ho, Robert L. Coleman	2016	127
9	Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies Cancer ·Myung‐Ju Ahn, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Lecia V. Sequist, Toyoaki Hida, James Chih‐Hsin Yang, Suresh S. Ramalingam, Tetsuya Mitsudomi, Pasi A. Jänne, Helen Mann, Mireille Cantarini, Glenwood Goss	2018	102
10	Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset Journal of Thoracic Oncology ·Byoung Chul Cho, B. Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Virote Sriuranpong, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, Jong Seok Lee, Helen Mann, Matilde Saggese, Thanyanan Reungwetwattana, Suresh S. Ramalingam, Yuichiro Ohe	2018	96
11	Family carers of stroke survivors: needs, knowledge, satisfaction and competence in caring Disability and Rehabilitation ·Ann Mackenzie, Lin Perry, Elizabeth Lockhart, Mark Cottee, Geoffrey Cloud, Helen Mann	2006	94
12	Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals European Journal of Radiology ·Binsheng Zhao, Yongqiang Tan, Daniel J. Bell, Sarah Elizabeth Marley, Pingzhen Guo, Helen Mann, Marietta Scott, Lawrence H. Schwartz, Dana Ghiorghiu	2013	74
13	Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial Clinical Lung Cancer ·John V. Heymach, Tetsuya Mitsudomi, David H. Harpole, Mike Aperghis, Stephanie Jones, Helen Mann, Tamer M. Fouad, Martin Reck	2021	74
14	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer Clinical Cancer Research ·Emer O. Hanrahan, Anderson J. Ryan, Helen Mann, S. Kennedy, Peter Langmuir, Ronald B. Natale, Roy S. Herbst, Bruce E. Johnson, John V. Heymach	2009	69
15	ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection Clinical Lung Cancer ·Yi‐Long Wu, Roy S. Herbst, Helen Mann, Yuri Rukazenkov, Marcelo Marotti, Masahiro Tsuboi	2018	64
16	Epidermal growth factor receptor immunohistochemistry Cancer ·Fred R. Hirsch, Rafał Dziadziuszko, Nick Thatcher, Helen Mann, Claire Watkins, Dinah V. Parums, Georgina Speake, Brian R. Holloway, Paul A. Bunn, Wilbur A. Franklin	2008	61
17	Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer British Journal of Cancer ·Pasi A. Jänne, Ian C. P. Smith, Gael McWalter, Helen Mann, Brian Dougherty, Jill Walker, Maria Orr, Darren Hodgson, Alice T. Shaw, José Rodrigues Pereira, G. Jeannin, Johan Vansteenkiste, C.H. Barrios, Fábio Franke, Lucio Crinò, Paul D. Smith	2015	59
18	Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC Cancer Research ·John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck	2023	58
19	Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC Journal of Thoracic Oncology ·Jarushka Naidoo, Scott Antonia, Yi‐Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann, Michael Newton, Corinne Faivre‐Finn	2023	48
20	LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study Annals of Oncology ·Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sofia Oliveira, Moïshe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero	2023	48

About Helen Mann

Helen Mann is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Cancer Research, having authored 95 papers that have together received 6.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (36 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Research Studies (12 papers), Colorectal Cancer Treatments and Studies (11 papers), PARP inhibition in cancer therapy (11 papers), Pancreatic and Hepatic Oncology Research (9 papers), Gastric Cancer Management and Outcomes (8 papers) and Advanced Breast Cancer Therapies (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.0k citations), Oncology (2.9k citations), Cancer Research (892 citations), Reproductive Medicine (171 citations) and Molecular Biology (1.3k citations). Helen Mann has collaborated with scholars based in United Kingdom, United States and Japan. Frequent co-authors include Suresh S. Ramalingam, Serban Ghiorghiu, Yi‐Long Wu, Frances A. Shepherd, Myung‐Ju Ahn, Tony Mok, Chee Khoon Lee, Willemijn S.M.E. Theelen, Marcelo Marotti and Vassiliki A. Papadimitrakopoulou. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Lung Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Helen Mann

Impact in

Papers in i

In The Last Decade

Helen Mann

Helen Mann's Hit Papers

Peers

Countries citing papers authored by Helen Mann

Fields of papers citing papers by Helen Mann

All Works

About Helen Mann

Explore authors with similar magnitude of impact

Papers in